{
  "id": "SQ-LIP-000020",
  "question": "How does lipedema affect quality of life, depression, and anxiety in affected patients?",
  "question_pt": "Como o lipedema afeta a qualidade de vida, a depressão e a ansiedade nos pacientes acometidos?",
  "phrasings": [
    "What impact does lipedema have on the wellbeing, depression, and anxiety levels of people who have it?",
    "In patients with lipedema, what are the effects on quality of life and on symptoms of depression and anxiety?",
    "lipedema effects quality of life depression anxiety patients",
    "To what extent does living with lipedema influence mental health, including depression and anxiety, and overall quality of life?"
  ],
  "phrasings_pt": [
    "Qual o impacto do lipedema no bem-estar, na depressão e nos níveis de ansiedade das pessoas que o têm?",
    "Em pacientes com lipedema, quais são os efeitos sobre a qualidade de vida e os sintomas de depressão e ansiedade?",
    "lipedema efeitos qualidade de vida depressão ansiedade pacientes",
    "Até que ponto conviver com lipedema influencia a saúde mental, incluindo depressão e ansiedade, e a qualidade de vida em geral?"
  ],
  "knowledge_state": "speculative",
  "tags": [
    "Mental health",
    "Comorbidities"
  ],
  "keywords": [
    "quality of life",
    "depression",
    "anxiety",
    "psychological burden"
  ],
  "current_answer": "Based on currently indexed evidence, lipedema is consistently associated with reduced quality of life and elevated depressive and anxiety symptoms, though the entire evidence base is observational (cross-sectional studies and one scoping review) and graded low-to-moderate, so causal and magnitude inferences remain tentative. For quality of life, multiple cross-sectional cohorts report scores below general-population norms across WHOQOL-BREF, SF-36, EQ-5D-3L and RAND-36 instruments (e.g. WHOQOL-BREF psychological ~46 and physical ~45-51; SF-36 total 57.4/100; EQ-5D-3L 66.1 vs 85 Dutch population), with the psychological domain often most affected (SCR-LIP-000167, -000170, -000171, -000178). For depression, indexed studies report a high but variable burden: PHQ-9 means around 10-12 with 50-59% scoring >=10 in several cohorts, self-reported depression 43.6% vs 18.5% in BMI/age/sex-matched controls, and depression prevalence of 22.7-42% in the scoping review (SCR-LIP-000167, -000169, -000170, -000175). For anxiety, available studies report markedly elevated symptoms versus healthy controls, including after BMI adjustment in a small case-control study (HAM-A 27.6 vs 5.0) (SCR-LIP-000172, -000176). Quality of life appears strongly linked to mood and symptom burden: depression severity, appearance-related distress, lower mobility, pain, symptom severity and health-related stigma independently predict or correlate with worse QoL (regression models explaining 23.5-73% of QoL variance; QoL–depression r up to -0.75) (SCR-LIP-000170, -000171, -000173, -000174). An important refinement (moderate-grade) is that when lipedema patients are compared specifically with overweight/obese women rather than healthy or general-population controls, disability remains significantly worse after BMI adjustment, but depression (BDI-II, HADS-D) and anxiety (HADS-A) show NO significant difference, suggesting some of the mood burden attributed to lipedema may overlap with that of obesity (SCR-LIP-000177). Comorbidities and correlates flagged in lower-grade studies include fibromyalgia (associated with higher anxiety/depression and lower QoL), longer disease duration, higher BMI, and low serum vitamin D (SCR-LIP-000168, -000175, -000176).",
  "current_answer_pt": "Com base nas evidências atualmente indexadas, o lipedema está consistentemente associado a qualidade de vida reduzida e a sintomas depressivos e ansiosos elevados, embora toda a base de evidências seja observacional (estudos transversais e uma revisão de escopo) e classificada como de baixa a moderada qualidade, de modo que inferências causais e de magnitude permanecem provisórias. Para a qualidade de vida, múltiplas coortes transversais relatam pontuações abaixo das normas populacionais gerais em diversos instrumentos (WHOQOL-BREF, SF-36, EQ-5D-3L e RAND-36) — por exemplo, WHOQOL-BREF psicológico ~46 e físico ~45-51; SF-36 total 57,4/100; EQ-5D-3L 66,1 vs 85 na população holandesa —, com o domínio psicológico frequentemente o mais afetado (SCR-LIP-000167, -000170, -000171, -000178). Para depressão, os estudos indexados relatam uma carga alta mas variável: médias de PHQ-9 em torno de 10-12 com 50-59% pontuando >=10 em várias coortes, depressão autorrelatada de 43,6% vs 18,5% em controles pareados por IMC/idade/sexo, e prevalência de depressão de 22,7-42% na revisão de escopo (SCR-LIP-000167, -000169, -000170, -000175). Para ansiedade, os estudos disponíveis relatam sintomas marcadamente elevados em relação a controles saudáveis, inclusive após ajuste por IMC em um pequeno estudo caso-controle (HAM-A 27,6 vs 5,0) (SCR-LIP-000172, -000176). A qualidade de vida parece fortemente ligada ao humor e à carga de sintomas: gravidade da depressão, sofrimento relacionado à aparência, menor mobilidade, dor, gravidade dos sintomas e estigma relacionado à saúde predizem ou se correlacionam independentemente com pior qualidade de vida (modelos de regressão explicando 23,5-73% da variância; correlação QoL–depressão de até -0,75) (SCR-LIP-000170, -000171, -000173, -000174). Um refinamento importante (qualidade moderada) é que, quando pacientes com lipedema são comparados especificamente com mulheres com sobrepeso/obesidade em vez de controles saudáveis ou da população geral, a incapacidade permanece significativamente pior após ajuste por IMC, mas depressão (BDI-II, HADS-D) e ansiedade (HADS-A) não mostram diferença significativa, sugerindo que parte da carga de humor atribuída ao lipedema pode se sobrepor à da obesidade (SCR-LIP-000177). Comorbidades e correlatos sinalizados em estudos de menor qualidade incluem fibromialgia (associada a maior ansiedade/depressão e menor qualidade de vida), maior duração da doença, maior IMC e baixos níveis séricos de vitamina D (SCR-LIP-000168, -000175, -000176).",
  "major_uncertainty": "The central unresolved issue is causal attribution: nearly all evidence is cross-sectional and confounded by obesity, and the strongest comparison against an appropriate control group (overweight/obese women) found no significant difference in depression or anxiety after BMI adjustment (SCR-LIP-000177), directly conflicting with small healthy-control studies reporting large BMI-adjusted differences (SCR-LIP-000172). It remains unclear how much of the observed mood and QoL burden is specific to lipedema versus shared with obesity, pain, or stigma; no longitudinal or interventional data establish directionality, and reported depression/anxiety magnitudes vary widely across small cohorts with unknown risk of bias.",
  "version": "1.2",
  "created": "2026-05-31",
  "updated": "2026-05-31",
  "evidence_direction": {
    "supporting": 11,
    "contradicting": 0,
    "other": 1
  },
  "knowledge_freshness": {
    "pct": 92,
    "sources": 12,
    "newest": 2025,
    "oldest": 2018,
    "label": "current evidence base"
  },
  "claims": [
    {
      "id": "SCR-LIP-000167",
      "role": "supporting",
      "statement": "In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity."
    },
    {
      "id": "SCR-LIP-000168",
      "role": "supporting",
      "statement": "In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001)."
    },
    {
      "id": "SCR-LIP-000169",
      "role": "supporting",
      "statement": "In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001)."
    },
    {
      "id": "SCR-LIP-000170",
      "role": "supporting",
      "statement": "In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance)."
    },
    {
      "id": "SCR-LIP-000171",
      "role": "supporting",
      "statement": "In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75)."
    },
    {
      "id": "SCR-LIP-000172",
      "role": "supporting",
      "statement": "In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001)."
    },
    {
      "id": "SCR-LIP-000173",
      "role": "supporting",
      "statement": "In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression."
    },
    {
      "id": "SCR-LIP-000174",
      "role": "supporting",
      "statement": "In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL."
    },
    {
      "id": "SCR-LIP-000175",
      "role": "supporting",
      "statement": "In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment."
    },
    {
      "id": "SCR-LIP-000176",
      "role": "supporting",
      "statement": "In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511)."
    },
    {
      "id": "SCR-LIP-000177",
      "role": "refines",
      "statement": "Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment."
    },
    {
      "id": "SCR-LIP-000178",
      "role": "supporting",
      "statement": "In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata."
    }
  ],
  "references": [
    "DOI:10.3389/fgwh.2025.1629077",
    "DOI:10.1089/lrb.2023.0038",
    "DOI:10.3390/life14030295",
    "DOI:10.1186/s12905-021-01174-y",
    "DOI:10.3390/ijerph181910223",
    "DOI:10.3390/ijerph192013679",
    "DOI:10.1080/13548506.2018.1459750",
    "DOI:10.1080/07399332.2025.2499487",
    "DOI:10.1089/lrb.2024.0117",
    "DOI:10.1515/hmbci-2021-0027",
    "DOI:10.17219/acem/181146",
    "DOI:10.1186/s12905-025-03834-9"
  ],
  "cite": "Scientific Claim Registry. How does lipedema affect quality of life, depression, and anxiety in affected patients?. SQ-LIP-000020 v1.2; 2026-05-31. https://scientificclaims.org/q/SQ-LIP-000020/v1.2.html",
  "versions": [
    {
      "version": "1.2",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000020/v1.2.html"
    },
    {
      "version": "1.1",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000020/v1.1.html"
    },
    {
      "version": "1.0",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000020/v1.0.html"
    }
  ],
  "url": "https://scientificclaims.org/q/SQ-LIP-000020.html",
  "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000020.html",
  "version_url": "https://scientificclaims.org/q/SQ-LIP-000020/v1.2.html",
  "license": "CC-BY-4.0",
  "disclaimer": "Evidence-bounded summary; not medical advice."
}